Abstract 911 – Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (48%, 14 Votes)
Abstract 1955 – Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (41%, 12 Votes)
Abstract 3028 – A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (38%, 11 Votes)
Abstract 1725 – Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (34%, 10 Votes)
Hope everyone had a great time at #ACR16! (In real life or virtually on Twitter)
Greetings and Happy Holidays #RheumJC friends!
For our next session of #RheumJC, we’ll be discussing some of our favorite abstracts from #ACR16. Since we were only able to narrow our list down to 9 abstracts among our team, we’re polling you to decide which abstracts we’ll be discussing for the next journal club.
Also, in hopes of increasing everyone’s ability to participate, we’re also polling on what day of the week and times that work best for you. Over the next year of #RheumJC, we’ll likely plan on mixing up the day of the week and time so that over time everyone has an opportunity to participate.
If you would like to see the full abstract, please check acrabstracts.org (unfortunately, our polling plugin doesn’t allow links).
What #ACR16 abstracts should #RheumJC discuss for the next journal club? (Choose up to 4)
911 - Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (48%, 14 Votes)
1955 - Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (41%, 12 Votes)
3028 - A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (38%, 11 Votes)
1725 - Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (34%, 10 Votes)
3225 - Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with RA (31%, 9 Votes)
3169 - Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study (24%, 7 Votes)
1957 - No Increased Risk of Chronic Kidney Disease with Allopurinol Use (21%, 6 Votes)
86 - Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture (14%, 4 Votes)
2987 - Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study (10%, 3 Votes)
Total Voters: 29
What day of the week should we hold #RheumJC? (choose all days that would work for you)
Wednesday (47%, 9 Votes)
Thursday (47%, 9 Votes)
Tuesday (37%, 7 Votes)
Sunday (32%, 6 Votes)
Friday (32%, 6 Votes)
Monday (26%, 5 Votes)
Saturday (26%, 5 Votes)
Total Voters: 19
What time of day would best allow you to participate in #RheumJC? (choose all times that would work for you)
Dr. Gottenberg (@jegotten) is a staff rheumatologist with the Department of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Strasbourg University Hospital, Université de Strasbourg, Strasbourg, France.
JAMA has graciously made Dr. Gottenberg’s article and the related article free to access for 48 hours beginning October 26th
Fibroblast image by Heiti Paves (Own work) [CC BY-SA 3.0], via Wikimedia Commons.
The next session of #RheumJC will be Thursday, June 2, 2016, discussing a recent article from The Lancet by Khanna, D., et al, looking at the role of IL–6 blockage in scleroderma, titled Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Greetings rheumatology friends! The next session of #RheumJC will be Thursday, May 5, 2016, where we will be discussing secukinumab, an anti-interleukin–17A monoclonal antibody that was recently FDA approved for the treatment of psoriatic arthritis. The article we’ll be discussing was published in October 2015 in the New England Journal of Medicine and is titled Secukinumab Inhibition of Interleukin–17A in Patients with Psoriatic Arthritis. We again expect a lively discussion about this new treatment option.
If you are participating in a Twitter journal club chat for the first time, please read our Getting Started Guide to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:
Please remember to try to stay on topic whenever possible.
Be polite and courteous.
Do not violate HIPAA.
As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at firstname.lastname@example.org.